**AI-based Clinical Trial Solution Providers Market Trends Growth & Analysis**

Research Nester has published a detailed market report on ‘[Global AI-based Clinical Trial Solution Providers Market](https://www.researchnester.com/reports/ai-based-clinical-trial-solution-providers-market/3859)’ for the forecast period, i.e. 2023 – 2035 which includes factors, such as, market growth over the forecast period, detailed regional synopsis, market segmentation, growth drivers, and key market players and their detailed profiling.

**Global AI-based Clinical Trial Solution Providers Market Size:**

The global AI-based clinical trial solution providers market is estimated to grow at a CAGR of ~22% over the forecast period. The market is estimated to garner a revenue of ~USD 12 billion by the end of 2035.. Market growth is attributed to increasing demand for drug development and testing, fueled by the increasing prevalence of infectious diseases. Moreover, it is estimated that the increasing adoption of AI-based technologies by pharmaceutical companies will further increase the demand for AI-based clinical trials. At the same time, increasing penetration of artificial intelligence is expected to drive the market growth. Moreover, technological developments in the healthcare sector, supported by increased R&D activities, are estimated to further drive the market growth. According to World Health Organization statistics released in the year 2021, the proportion of gross domestic expenditure on health research and development (health GERD) to total GERD is highest in the Eastern Mediterranean at 14.8%, followed by the Americas at 12.8% and Southeast Asia at 12.4%.

**Request Free Sample Copy of this Report @ [https://www.researchnester.com/sample-request-3859**](https://www.researchnester.com/sample-request-3859)** 

**Global AI-based Clinical Trial Solution Providers Market: Key Takeaways** 

- Market in Asia Pacific to propel highest growth
- The oncology segment to garner the highest growth
- Market in North America to grow at a highest rate

**Spiking Digitization in Various Sectors Across the World to Boost Market Growth**

Rising demand for increased productivity in various companies across the globe and increasing demands to ensure regulatory compliance and avoid compliance errors are expected to be factors driving the growth of the global AI-based clinical trial solution providers market. For enterprises, digital and AI based services provide the enhanced visibility and control they need to manage the changes associated with the risks of high volumes of traffic that have increased over the years. Therefore, it is expected to be another important factor driving the growth of the market. Additionally, cloud-based AI services have grown worldwide over the years. For instance, cloud-based services are expected to grow by 30% in the year 2023 and are estimated to grow even more during the forecast period. Hence, it is also estimated to boost market growth significantly during the forecast period. AI can identify suitable clinical trial cohorts by analyzing medical records and social media content. Accelerate trial recruitment by using AI technology to inform medical staff and patients of trial opportunities and simplify eligibility criteria to make them more accessible to potential participants. Clinical trials of new molecules consume most of the time and budget of the drug discovery process. AI has been used to improve the quality of study design, patient selection, dose selection, patient adherence, study monitoring, and endpoint analysis. GSK is one of the most active pharmaceutical companies applying artificial intelligence to drug discovery. This was one of the first internally created artificial intelligence units.

**Global AI-based Clinical Trial Solution Providers Market: Regional Overview**

The global AI-based clinical trial solution providers market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region.

**Constant Growth of IT Infrastructure in Healthcare to Drive Market Growth in the Asia Pacific Region**

The market for AI-based clinical trial solution providers in the Asia Pacific region is estimated to garner the largest revenue by the end of 2035. The regional growth can be largely attributed to the steady growth of IT infrastructure in healthcare and the growing demand for AI-based clinical trial solutions. Market expansion in this region is expected to be further fueled by the increasing implementation of the GS1 standard in the region for tracking drug visibility. The World Health Organization (WHO) says most of the trafficking of counterfeit medicines occurs in the Asia-Pacific region. For instance, only 8% of substandard or counterfeit reports to the WHO came from the WHO Western Pacific Region, 6% from the WHO Eastern Mediterranean Region, and only 2% from the WHO South-East Asia Region. To thwart drug counterfeiting, the pharmaceutical sector is implementing cloud management, barcodes, and other scanning technologies to track items and collect information about them. Hence, these factors are expected to influence regional market growth.

**Growing Healthcare Expenditure to Propel Market Growth in the North American Region**

The market for AI-based clinical trial solution providers in the North American region is estimated to garner the highest CAGR by the end of 2035. Growth of the market in the region is primarily driven by rising healthcare costs and rising disposable incomes, which drive demand for advanced technological developments in the healthcare sector. According to the Centers for Medicare & Medical Services (CMS), U.S. national health care spending increased 9.7% to USD 4.1 trillion (USD 12,350 per capita) in 2020. Additionally, the presence of strong healthcare networks in the region and the availability of regulatory support guidelines have allowed enterprises to find more viable solutions to develop efficient treatment and drug management options. Furthermore, it encourages market participants to decide to invest in more research and development. It is expected to contribute to the growth of the market in this region. Additionally, as North American consumers increasingly prefer online platforms for a variety of services, businesses are focusing on improving their application management services. According to the World Bank, 91% of the US population uses the Internet personally, and this percentage is estimated to increase significantly during the forecast period. Therefore, it is estimated that this will also contribute significantly to the growth of the market in the region.

**Request for customization @ [https://www.researchnester.com/customized-reports-3859**](https://www.researchnester.com/customized-reports-3859)**

The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in:  

- North America (U.S., Canada)  
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe)  
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America)  
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)
- Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). 

**Global AI-based Clinical Trial Solution Providers Market, Segmentation by Application**

- Oncology
- Cardiovascular Diseases
- Metabolic Diseases 
- Others

Amongst these four segments, the oncology segment is anticipated to hold the largest share over the forecast period. The growth of the segment can be accredited to the increased cancer prevalence and demand for effective cancer treatments. Oncology is the branch of medicine that deals with the research, treatment, diagnosis, and prevention of cancer. An oncologist is a medical professional who practices oncology. Moreover, the shortage of cancer therapeutics is estimated to increase the demand for clinical trials, which is expected to boost the growth of the segment. According to the World Health Organization (WHO), about 10 million people died of cancer in the year 2020. The most common cancer deaths were lung cancer with 1.8 million deaths, colon and rectal cancer with 916,000 deaths, liver cancer with 830,000 deaths, stomach cancer with 769,000 deaths, and breast cancer with 685,000 deaths.

**Global AI-based Clinical Trial Solution Providers Market, Segmentation by End User**

- Pharmaceutical Companies
- Academic Researcher
- Others

Amongst these three segments, the pharmaceutical companies segment is anticipated to hold a significant share over the forecast period. The pharmaceutical industry discovers, develops, manufactures, and markets medicines or drugs for use as medicines administered to patients to cure, immunize, or alleviate symptoms. Pharmaceutical companies may deal in generic or branded drugs and medical devices. The growth of this segment is owing to the fact that it is the fastest-growing industry in the world. In addition, an increase in people's credit ratings affects the purchasing power of customers. Therefore, retail pharmacists build customer relationships and increase their dependence on retail outlets. Trust is built because direct contact with people increases consumer confidence when buying medicines. This improves loyalty rates for pharmaceutical companies. The number of retail pharmacies in the United States was noted to be about 60,000 out of a total of 67,000 pharmacy facilities by the year 2021.

Few of the well-known market leaders in the global AI-based clinical trial solution providers market that are profiled by Research Nester are are Innoplexus AG, Antidote Technologies, Inc., Saama Technologies Pvt. Ltd., Unlearn.AI, Inc., Deep 6 AI Inc., Median Technologies, BioAge Labs, Inc., AiCure, LLC, ConsilX, and other key market players.

**Contact for more Info:**

**AJ Daniel**

**Email: info@researchnester.com**

**U.S. Phone: +1 646 586 9123** 

**U.K. Phone: +44 203 608 5919**


